Redacid

Our extensive in vitro studies have shown that DLBS2411 decreases the level of H+/K+ ATPase mRNA expression in a dose-dependent manner. The analysis of enzyme kinetics revealed that DLBS2411 acts as a competitive inhibitor of the enzyme. It was also demonstrated that DLBS2411 is effective under various pH conditions, particularly at low gastric pH. This suggests that DLBS2411 could be a potent pharmacological agent for suppressing hyperacidity in clinical settings and reducing gastric ulceration.

Additionally, DLBS2411 has been studied for its protective effects on the gastric and colon mucosa through several pathways. It stimulates the synthesis of gastric and colon mucus by elevating the phosphorylation of IKKα and activating NF-κB, which promotes the transcription of MUC5AC and COX-2, leading to an increase in nitric oxide (NO) production. The high levels of NO resulting from NF-κB expression enhance mucosal blood flow. Therefore, it is clear that DLBS2411 promotes mucus healing by stimulating the synthesis and secretion of gastric mucus.

In vivo studies have also confirmed the efficacy of DLBS2411 as an H+/K+ ATPase inhibitor and gastroprotector. In experiments involving indomethacin and ethanol-induced rats, treatment with DLBS2411 resulted in a reduction in the number of petechiae, suggesting its gastroprotective properties. Another study using acetic acid-induced rats indicated that DLBS2411 was comparable to omeprazole and sucralfate in reducing ulcer severity, as shown by histopathological results. In a further animal study with ethanol-induced rats, DLBS2411 effectively protected the stomach lining, as evidenced by the percentage of ulceration inhibition and the ulcerative lesion index.

Another significant advantage of DLBS2411 is its potent antioxidant activity.